膜联蛋白A8在卵巢上皮性浆液性肿瘤中的表达及临床意义

目的:检测膜联蛋白A8(Annexin A8,ANXA8)在卵巢组织中的表达,探讨其表达与卵巢上皮性浆液性恶性肿瘤患者临床病理参数及预后的相关性。方法:采用免疫组织化学法检测75例卵巢组织(正常卵巢组织组11例、卵巢浆液性良性肿瘤组13例、卵巢浆液性交界性肿瘤组17例、卵巢浆液性恶性肿瘤组34例)中ANXA8的表达,分析其与卵巢癌患者临床病理参数及疾病预后的关系。结果:ANXA8主要定位于细胞膜及细胞质,ANXA8在卵巢浆液性恶性肿瘤组中的高表达率(23/34,67.65%)明显高于正常卵巢组织组(1/11,9.09%)、卵巢浆液性良性肿瘤组(3/13,23.08%)及卵巢浆液性交界性肿瘤组(5/17,29.41%),差异有统计学意义(P分别为0.001、0.006、0.010)。在34例卵巢浆液性恶性肿瘤患者中,FIGOⅢ~Ⅳ期患者的ANXA8的高表达率(21/24,87.5%)明显高于FIGOⅠ~Ⅱ期患者(2/10,20.0%),差异具有统计学意义(P<0.001);盆腹腔残余病灶直径>1 cm患者的ANXA8高表达率(15/17,88.2%)明显高于残余病灶≤1 cm患者(8/17,41.2%),差异有统计学意义(P=0.010)。Kaplan-Meier生存分析表明,FIGO分期、淋巴转移、残余病灶、ANXA8的表达都是影响总生存期(OS)的重要因素(均P<0.05)。Cox多元回归分析表明ANXA8的高表达是影响卵巢浆液性恶性肿瘤患者预后的独立危险因素(P=0.019,HR=11.465,95%CI:1.498~87.757)。结论:ANXA8在卵巢上皮性浆液性恶性肿瘤组织中表达升高,且与卵巢癌不良预后有关,可用于临床监测卵巢上皮性浆液性恶性肿瘤患者病情变化。

The Expression and Clinical Significance of Annexin A8 in Ovarian Epithelial Serous Tumors

Objective:To detect the expression of Annexin A8(ANXA8) in ovarian tissues and to investigate the relationship between its expression and clinicopathological parameters as well as prognosis in patients with ovarian epithelial serous carcinoma.Methods:Immunohistochemical(IHC) staining(SP method) for ANXA8 was conducted on tissues of 11 cases of normal ovaries, 13 cases of benign serous ovarian tumors, 17 cases of borderline serous ovarian tumors and 34 cases of malignant epithelial serous ovarian tumors, IHC results were compared to the clinical pathological parameters and prognosis of these malignant tumors. Results:The expression of ANXA8 was mainly located in cell membrane and cytoplasm, its high positive expression rate in epithelial serous ovarian carcinoma(23/34, 67.65%) was significantly higher than those in normal(1/11, 9.09%), benign(3/13, 23.08%) and borderline(5/17, 29.41%) epithelial serous ovarian tumors(P=0.001, 0.006, 0.010, respectively). Among these 34 cases of epithelial serous ovarian carcinoma, the high positive expression rate of ANXA8 in FIGO Stages Ⅲ-Ⅳ(21/24, 87.5%) was significantly higher than Stages Ⅰ-Ⅱ(2/10, 20.0%), P<0.001;and the high positive expression rate of ANXA8 in patients with residual tumor size >1 cm(15/17, 88.2%) was significantly higher than ≤1 cm(8/17, 41.2%), P=0.010. Kaplan-Meier survival analysis showed that FIGO stage, lymph node metastasis, residual tumor, as well as high expression of ANXA8 were associated with a shorter overall survival(OS, all P<0.05), multivariate Cox survival analysis demonstrated that high expression of ANXA8 was an independent risk factor for prognosis of epithelial serous ovarian carcinoma patients(P =0.019, HR =11.465, 95% CI: 1.498-87.757). Conclusions:The expression of ANXA8 was obviously increased in epithelial serous ovarian cancer and associated with poor prognosis of ovarian carcinoma, it can be used for clinical monitoring of patients with epithelial serous ovarian carcinoma.